Specific Antinuclear Antibody Level Changes after B Cell Depletion Therapy in Systemic Sclerosis Are Associated with Improvement of Skin Thickening

J Rheumatol. 2016 Jan;43(1):247-9. doi: 10.3899/jrheum.150105.

Authors

Carolien Bonroy¹, Vanessa Smith², Ellen Deschepper³, Filip De Keyser², Katrien Devreese⁴

Affiliations

¹ Adjunct Head of Clinics, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University Hospital; carolien.bonroy@uzgent.be.
² Department of Rheumatology, Ghent University Hospital;
³ Biostatistics Unit, Department of Public Health, Ghent University;
⁴ Department of Clinical Chemistry, Microbiology and Immunology, Ghent University Hospital, Ghent, Belgium.

PMID: 26724322
DOI: 10.3899/jrheum.150105

No abstract available

Publication types

Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Antineutrophil Cytoplasmic / blood
Antibodies, Antineutrophil Cytoplasmic / drug effects*
B-Lymphocytes / drug effects
Confidence Intervals
Female
Follow-Up Studies
Humans
Lymphocyte Depletion / methods*
Male
Rituximab / therapeutic use*
Scleroderma, Systemic / drug therapy*
Scleroderma, Systemic / immunology*
Skin / drug effects
Skin / pathology*
Treatment Outcome

Substances

Antibodies, Antineutrophil Cytoplasmic
Rituximab

Associated data

ClinicalTrials.gov/NCT00379431